Department of Pharmacy, Massachusetts General Hospital, USA.
Department of Pharmacy, University of Maryland Medical Center, USA.
Int J Surg. 2014 Dec;12(12):1416-9. doi: 10.1016/j.ijsu.2014.10.022. Epub 2014 Oct 28.
Achievement of early therapeutic anticoagulation with unfractionated heparin (UFH) is associated with improved outcomes in thromboembolic disease. Weight based UFH expedites time to therapeutic anticoagulation. Treatment with UFH is challenging in surgical patients due to their high propensity for bleeding. We sought to test the hypothesis that an initial weight based UFH infusion in surgical patients increases the percentage of patients who achieve early therapeutic anticoagulation without increasing the risk of hemorrhagic events.
Using a non-concurrent retrospective cohort study design, adult surgical patients receiving UFH for venous thromboembolism (VTE) at a tertiary care center were included. Two groups were identified: the weight based (WB) and the under-dosed (UD) heparin groups. For our primary outcome, we compared percentage of patients in each group that achieved a therapeutic PTT within 24 h. Secondary outcomes included the incidence of supratherapeutic PTT levels, hemorrhagic events, and complications associated with VTE.
73 subjects met study criteria, which included 8 subjects in the WB group and 65 in the UD group. The demographic, baseline laboratory, admitting service and type of VTE were similar between the 2 groups. The percentages of WB and UD subjects who achieved a therapeutic PTT within 24 h were 75% and 28%, respectively (p < 0.01). There was no difference in the incidence of supratherapeutic PTT or hemorrhagic events.
Surgical patients who received an initial weight based UFH infusion achieved earlier therapeutic anticoagulation compared to under-dosed UFH without increasing the occurrence of supratherapeutic PTT levels or hemorrhagic events.
使用未分级肝素 (UFH) 实现早期治疗性抗凝与血栓栓塞性疾病的改善结果相关。基于体重的 UFH 可加快达到治疗性抗凝的时间。由于外科患者出血倾向高,因此在外科患者中使用 UFH 治疗具有挑战性。我们试图检验以下假设:外科患者初始基于体重的 UFH 输注会增加达到早期治疗性抗凝的患者比例,而不会增加出血事件的风险。
采用非同期回顾性队列研究设计,纳入在三级护理中心接受 UFH 治疗静脉血栓栓塞症 (VTE) 的成年外科患者。确定了两组:基于体重(WB)和低剂量(UD)肝素组。对于我们的主要结局,我们比较了每组中在 24 小时内达到治疗性 PTT 的患者比例。次要结局包括超治疗性 PTT 水平、出血事件以及与 VTE 相关的并发症的发生率。
73 名患者符合研究标准,其中包括 WB 组 8 名患者和 UD 组 65 名患者。两组患者的人口统计学、基线实验室、入院科室和 VTE 类型相似。在 24 小时内达到治疗性 PTT 的 WB 和 UD 患者的百分比分别为 75%和 28%(p<0.01)。超治疗性 PTT 或出血事件的发生率无差异。
与低剂量 UFH 相比,接受初始基于体重 UFH 输注的外科患者更早实现治疗性抗凝,而不会增加超治疗性 PTT 水平或出血事件的发生。